Bliss GVS Pharma Issues 75,250 Equity Shares Under ESOP
By Ankur Chandra | Published at: Jun 6, 2025 04:40 PM IST
Mumbai, June 6, 2025: Bliss GVS Pharma Ltd (NSE: BLISSGVS | BSE: 506197) has issued 75,250 equity shares under its Employee Stock Option Plan (ESOP) 2019, following the successful exercise of options by eligible staff members.
As of 6 June 2025, Bliss GVS Pharma shares were trading at ₹137.51, reflecting a decline of 1.45% from the previous close of ₹139.54. The intraday range was ₹136.50 to ₹139.70. The stock’s 52-week range spans ₹101.01 to ₹185.50, with an all-time high of ₹221.00. Market capitalisation stood at ₹1,448 crore. Trading volume reached 272,339 shares with a value of ₹374.49 lakh. The stock’s P/E ratio is 17.19 and book value per share is ₹95.85.
Details of the Share Allotment
- Total shares allotted: 75,250 equity shares
- Face value per share: ₹1
- Exercise price per share: ₹43 (inclusive of ₹42 premium)
- Allotment date: June 6, 2025
- ISIN: INE416D01022
- Lock-in period: 6 months from the date of allotment (up to December 6, 2025)
Impact on Share Capital
This issuance has led to an increase in the company’s issued, subscribed, and paid-up share capital. The updated capital structure is as follows:
| Particulars | Pre-Allotment | Post-Allotment |
|---|---|---|
| Number of Equity Shares | 10,53,70,273 | 10,54,45,522 |
| Total Share Capital (₹) | 10,53,70,273 | 10,54,45,522 |
All newly allotted shares carry equal rights and obligations as the existing equity shares, ranking pari-passu in all respects.
Regulatory Compliance
The share allotment was carried out in line with Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. Bliss GVS Pharma had earlier secured in-principle approvals from both BSE and NSE for the ESOP 2019 scheme in 2020.
Strong Q4 & FY25 Financial Results
For the quarter ending March 31, 2025, Bliss GVS Pharma reported:
- Standalone net sales: ₹156.00 Cr (–4.8% YoY);
- Standalone net profit: ₹11.45 Cr, nearly 200% YoY growth;
- Consolidated net profit: ₹15.54 Cr (compared to –₹9.15 Cr YoY), on total income of ₹197.99 Cr (–0.07%).
Over FY25, the company recorded consolidated revenue of ₹846.21 Cr (+5.9%) and a net profit of ₹84.29 Cr (+12%), up from ₹75.45 Cr the previous year.
Ongoing ESOP Activity
The June 6 allotment follows previous tranches under ESOP 2019: 34,250 shares issued on December 6, 2024, and 4,000 shares on January 7, 2025. This reflects sustained support for employee ownership.
Regulatory & Compliance Highlights
- Bliss GVS Pharma’s EU‑GMP manufacturing certification (from Romania’s NAMMDR) for plants in Palghar was reaffirmed in November 2024.
- In May 2025, the company invoked arbitration proceedings in the Supreme Court to recover USD 1.69 M from Kenya‑based Pan Pharmaceuticals; provisions have been made
About Bliss GVS Pharma Ltd
Based in Mumbai, Bliss GVS Pharma Ltd is a prominent pharmaceutical company specialising in generics and therapeutic solutions for global markets. The company continues to integrate employee ownership initiatives such as ESOPs as a strategic component of its workforce development approach.
REF: https://nsearchives.nseindia.com/corporate/BLISSGVS_06062025124503_Outcome_of_ESOP_Allotment_Committee_sd.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
